The role of cost-effectiveness in the use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists

Eur J Prev Cardiol. 2023 Jun 1;30(8):656-657. doi: 10.1093/eurjpc/zwad032.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Consensus
  • Cost-Benefit Analysis
  • Diabetes Mellitus, Type 2* / diagnosis
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucagon-Like Peptide-1 Receptor / agonists
  • Glucose
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Sodium
  • Sodium-Glucose Transporter 2 Inhibitors* / adverse effects
  • Symporters*

Substances

  • Sodium-Glucose Transporter 2 Inhibitors
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Sodium
  • Symporters
  • Glucose